Prasad P, Bennett A, Speirs V, Shaaban A
Front Oncol. 2022; 12:875839.
PMID: 35814372
PMC: 9261459.
DOI: 10.3389/fonc.2022.875839.
Salehi Far S, Soltani M, Zardast M, Ghasemian Moghaddam M
J Cancer Epidemiol. 2021; 2021:4478155.
PMID: 34691180
PMC: 8536452.
DOI: 10.1155/2021/4478155.
Shen Y, Zhong J, Liu J, Liu K, Zhao J, Xu T
Oncol Rep. 2018; 39(6):2604-2612.
PMID: 29620287
PMC: 5983932.
DOI: 10.3892/or.2018.6350.
Oh H, Eliassen A, Beck A, Rosner B, Schnitt S, Collins L
NPJ Breast Cancer. 2017; 3:39.
PMID: 28979927
PMC: 5624935.
DOI: 10.1038/s41523-017-0041-7.
Danforth Jr D
Breast Cancer (Auckl). 2016; 10:109-46.
PMID: 27559297
PMC: 4990153.
DOI: 10.4137/BCBCR.S39384.
Histopathological Features of Non-Neoplastic Breast Parenchyma Do Not Predict BRCA Mutation Status of Patients with Invasive Breast Cancer.
Bayraktar S, Qiu H, Liu D, Shen Y, Gutierrez-Barrera A, Arun B
Biomark Cancer. 2015; 7:39-49.
PMID: 26327783
PMC: 4541461.
DOI: 10.4137/BIC.S29716.
Systems level-based RNAi screening by high content analysis identifies UBR5 as a regulator of estrogen receptor-α protein levels and activity.
Bolt M, Stossi F, Callison A, Mancini M, Dandekar R, Mancini M
Oncogene. 2014; 34(2):154-64.
PMID: 24441042
PMC: 4871123.
DOI: 10.1038/onc.2013.550.
Model of tumor-associated epigenetic changes of HER2, ER, and PgR expression in invasive breast cancer phenotypes.
Kurbel S
Tumour Biol. 2013; 34(4):2011-7.
PMID: 23640060
DOI: 10.1007/s13277-013-0809-9.
Lowering oral contraceptive norethindrone dose increases estrogen and progesterone receptor levels with no reduction in proliferation of breast epithelium: a randomized trial.
Hovanessian-Larsen L, Taylor D, Hawes D, Spicer D, Press M, Wu A
Contraception. 2012; 86(3):238-43.
PMID: 22325110
PMC: 3355208.
DOI: 10.1016/j.contraception.2011.12.015.
Anti-tumor effects of retinoids combined with trastuzumab or tamoxifen in breast cancer cells: induction of apoptosis by retinoid/trastuzumab combinations.
Koay D, Zerillo C, Narayan M, Harris L, DiGiovanna M
Breast Cancer Res. 2010; 12(4):R62.
PMID: 20696059
PMC: 2949655.
DOI: 10.1186/bcr2625.
ER re-expression and re-sensitization to endocrine therapies in ER-negative breast cancers.
Brinkman J, El-Ashry D
J Mammary Gland Biol Neoplasia. 2009; 14(1):67-78.
PMID: 19263197
DOI: 10.1007/s10911-009-9113-0.
ER-alpha36, a novel variant of ER-alpha, is expressed in ER-positive and -negative human breast carcinomas.
Lee L, Cao J, Deng H, Chen P, Gatalica Z, Wang Z
Anticancer Res. 2008; 28(1B):479-83.
PMID: 18383888
PMC: 2610490.
Quantification of angiogenesis in estrogen receptor-positive and negative breast carcinoma.
Parentes-Vieira J, Lopes-Costa P, Pires C, Dos Santos A, Pereira-Filho J, da Silva B
Int Semin Surg Oncol. 2007; 4:22.
PMID: 17718911
PMC: 2008197.
DOI: 10.1186/1477-7800-4-22.
Assessment of the proliferative, apoptotic and cellular renovation indices of the human mammary epithelium during the follicular and luteal phases of the menstrual cycle.
Navarrete M, Maier C, Falzoni R, Quadros L, Lima G, Baracat E
Breast Cancer Res. 2005; 7(3):R306-13.
PMID: 15987425
PMC: 1143573.
DOI: 10.1186/bcr994.
Distinct expression patterns of ER alpha and ER beta in normal human mammary gland.
Speirs V, Skliris G, Burdall S, Carder P
J Clin Pathol. 2002; 55(5):371-4.
PMID: 11986344
PMC: 1769648.
DOI: 10.1136/jcp.55.5.371.
Use of the autopsy to study ontogeny and expression of the estrogen receptor gene in human breast.
Bartow S
J Mammary Gland Biol Neoplasia. 2000; 3(1):37-48.
PMID: 10819503
DOI: 10.1023/a:1026641401184.
Epithelial proliferation and hormone receptor status in the normal post-menopausal breast and the effects of hormone replacement therapy.
Hargreaves D, Knox F, Swindell R, Potten C, Bundred N
Br J Cancer. 1998; 78(7):945-9.
PMID: 9764588
PMC: 2063113.
DOI: 10.1038/bjc.1998.606.
Expression of estrogen receptors during growth of human pancreatic adenocarcinoma cells (Capan-1)-relationship with differentiation.
Hollande E, Fanjul M, Houti N, Faye J, Courriere P
In Vitro Cell Dev Biol Anim. 1998; 34(7):593-9.
PMID: 9719420
DOI: 10.1007/s11626-998-0120-z.
Breast cancer: further metabolic-endocrine risk markers?.
STOLL B
Br J Cancer. 1997; 76(12):1652-4.
PMID: 9413957
PMC: 2228209.
DOI: 10.1038/bjc.1997.612.
Expression of the estrogen receptor gene in developing and adult human breast.
Boyd M, Hildebrandt R, Bartow S
Breast Cancer Res Treat. 1996; 37(3):243-51.
PMID: 8825136
DOI: 10.1007/BF01806506.